Every Vaccine Trial, by Country

Why Did Countries in Central Asia/the Middle East and Most of Africa Appear to be “Hesitant” About Vaccine Trials?

As I scan down the list and see which countries readily experimented on their citizens, I am struck by how few African and Middle Eastern countries participated. Turkey and United Arab Emirates experimented on their people pretty early, and South Africa was the exception on the African continent. The major countries that we hear about in the news in the Middle East did not test these vaccines on their people, or did not begin such experiments until other countries had tested them out for several months. Afghanistan had zero vaccine trials. Israel had two vaccine trials, and the first one began in December 2020. Why? What do they know that we don’t know?

Albania 

  1. COVID-19 Vaccine Effectiveness in Albanian Health Workers (COVEAL), Pfizer, World Health Organization

Argentina

  1. 1Gam-COVID-Vac Study to Evaluate the Immunogenicity and Safety of Heterologous SARS-CoV-2 Vaccine Schemes
  2. A Phase 1b Trial to Evaluate Safety and Effect of SAR443122 on Immune System in Severe COVID-19
  3. A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants (ENSEMBLE)
  4. A Study to Determine the Safety and Efficacy of SARS-CoV-2 mRNA Vaccine CVnCoV in Adults for COVID-19
  5. Clinical Trial to Evaluate the Efficacy, Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (COVID-19)
  6. Phase III Study of AZD7442 for Treatment of COVID-19 in Outpatient Adults (TACKLE)
  7. Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in Adults
  8. Strategies for Combining the First Component of Sputnik V With Other Adenoviral or mRNA-based Vaccines.
  9. Study of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine in Adults

Australia

  1. A Study on the Safety, Tolerability and Immune Response of SARS-CoV-2 Sclamp (COVID-19) Vaccine in Healthy Adults
  2. BCG Vaccination to Protect Healthcare Workers Against COVID-19 (BRACE)
  3. Evaluating the Safety, Tolerability and Immunogenicity of bacTRL-Spike Vaccine for Prevention of COVID-19
  4. Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS Nanoparticle Vaccine With/Without Matrix-M Adjuvant
  5. Immunogenicity and Safety of Adjuvanted SCB-2020S Vaccines in Adults
  6. Monovalent Recombinant COVID19 Vaccine (COVAX19)
  7. SCB-2019 as COVID-19 Vaccine
  8. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Neutralizing Antibody BGB-DXP593 in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)

Austria

  1. A Study to Assess Safety, Tolerability, and Immunogenicity of V591 (COVID-19 Vaccine) in Healthy Participants (V591-001)
  2. Study of Recombinant Protein Vaccines With Adjuvant as a Primary Series and as a Booster Dose Against COVID-19 in Adults 18 Years of Age and Older (VAT00002)

Bahrain

  1. A Study to Evaluate The Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) in Healthy Population Aged 18 Years Old and Above (COVID-19)
  2. Safety and Efficacy of COVID-19 Prime-boost Vaccine in Bahrain

Belarus

  1. Clinical Trial of Efficacy, Safety, and Immunogenicity of Gam-COVID-Vac Vaccine Against COVID-19 in Belarus

Belgium

  1. A Controlled Phase 2/3 Study of Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Vaccine (SCB-2019) for the Prevention of COVID-19 (SCB-2019)
  2. A Controlled Phase 2/3 Study of Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Vaccine (SCB-2019) for the Prevention of COVID-19 (SCB-2019)
  3. A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults (ENSEMBLE 2) (Janssen)
  4. A Study of Ad26.COV2.S in Adults (COVID-19)
  5. A Study to Assess Safety, Tolerability, and Immunogenicity of V591 (COVID-19 Vaccine) in Healthy Participants (V591-001)
  6. A Study to Determine the Safety and Efficacy of SARS-CoV-2 mRNA Vaccine CVnCoV in Adults for COVID-19
  7. A Study to Evaluate Safety, Reactogenicity and Immunogenicity of the SARS-CoV-2 mRNA Vaccine CVnCoV in Adults With Co-morbidities for COVID-19
  8. Clinical Trial to Evaluate the Safety and Immunogenicity of the COVID-19 Vaccine (COVID-19-101)
  9. COVID-19: Safety and Immunogenicity of a Reduced Dose of the BioNTech/Pfizer BNT162b2 Vaccine (REDU-VAC)
  10. Impact of the Immune System on Response to Anti-Coronavirus Disease 19 (COVID-19) Vaccine in Allogeneic Stem Cell Recipients (Covid Vaccin Allo)
  11. Phase III Double-blind, Placebo-controlled Study of AZD7442 for Pre-exposure Prophylaxis of COVID-19 in Adult. (PROVENT)

Brazil

  1. A Controlled Phase 2/3 Study of Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Vaccine (SCB-2019) for the Prevention of COVID-19 (SCB-2019)
  2. A Phase 1b Trial to Evaluate Safety and Effect of SAR443122 on Immune System in Severe COVID-19
  3. A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants (ENSEMBLE)
  4. A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults (ENSEMBLE 2) (Janssen)
  5. A Study of Ad26.COV2.S in Healthy Pregnant Participants (COVID-19) (HORIZON 1)
  6. A Study to Assess the Safety and Immunogenicity of the Coronavac Vaccine Against COVID-19
  7. An Effectiveness Study of the Sinovac’s Adsorbed COVID-19 (Inactivated) Vaccine (Projeto S)
  8. BCG Vaccination to Protect Healthcare Workers Against COVID-19 (BRACE) Bill and Melinda Gates Foundation
  9. Clinical Trial of Efficacy and Safety of Sinovac’s Adsorbed COVID-19 (Inactivated) Vaccine in Healthcare Professionals (PROFISCOV)
  10. Effectiveness of the Adsorbed Vaccine COVID-19 (Coronavac) Among Education and Public Safety Workers With Risk Factors for Severity (COVACMANAUS)
  11. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Neutralizing Antibody BGB-DXP593 in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)
  12. Study of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine in Adults
  13. Study to Evaluate the Safety and Efficacy of a Booster Dose of BNT162b2 Against COVID-19 in Participants ≥16 Years of Age.
  14. The Efficacy, Safety and Immunogenicity Study of Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19

Canada

  1. A Clinical Trial of a Prophylactic Plasmid DNA Vaccine for COVID-19 [Covigenix VAX-001] in Adults
  2. COVID-19 Vaccine in Immunosuppressed Adults With Autoimmune Diseases (COVIAAD)
  3. COVID-19 Vaccines Safety Tracking (CoVaST)
  4. Efficacy and Safety of VPM1002 in Reducing SARS-CoV-2 (COVID-19) Infection Rate and Severity (COBRA)
  5. Immunization With IMM-101 vs Observation for Prevention of Respiratory and Severe COVID-19 Related Infections in Cancer Patients at Increased Risk of Exposure (COV-IMMUNO)
  6. Mix and Match of the Second COVID-19 Vaccine Dose for Safety and Immunogenicity (MOSAIC)
  7. PTX-COVID19-B, an mRNA Humoral Vaccine, is Intended for Prevention of COVID-19 in a General Population. This Study is Designed to Evaluate Safety, Tolerability, and Immunogenicity of PTX-COVID19-B Vaccine in Healthy Seronegative Adults Aged 18-64
  8. Safety, Tolerability and Immunogenicinity of a Coronavirus-Like Particle COVID-19 Vaccine in Adults Aged 18-55 Years
  9. Safety, Tolerability, and Immunogenicity of the COVID-19 Vaccine Candidate (VBI-2902a).
  10. Study of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine in Adults
  11. Study to Evaluate the Safety and Efficacy of a Booster Dose of BNT162b2 Against COVID-19 in Participants ≥16 Years of Age.
  12. Tableted COVID-19 Therapeutic Vaccine (COVID-19)
  13. Third Dose of COVID-19 Vaccine in LTCF Residents
  14. Third Dose of Moderna COVID-19 Vaccine in Transplant Recipients

Chile

  1. A Phase 1b Trial to Evaluate Safety and Effect of SAR443122 on Immune System in Severe COVID-19
  2. A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants (ENSEMBLE)
  3. Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in Adults
  4. Reactogenicity, Safety, and Immunogenicity of Covid-19 Vaccine Booster (REFUERZO)

China

  1. A Clinical Trial of a Recombinant Adenovirus 5 Vectored COVID-19 Vaccine (Ad5-nCoV) With Two Doses in Healthy Adults
  2. A Phase I clinical trial to evaluate the safety, tolerance and preliminary immunogenicity of different doses of a SARS-CoV-2 mRNA vaccine in population aged 18-59 years and 60 years and above
  3. A Phase II Clinical Trial to Evaluate the Recombinant Vaccine for COVID-19 (Adenovirus Vector) (CTII-nCoV)
  4. A Phase Ⅱ Clinical Trial of Recombinant Corona Virus Disease-19 (COVID-19) Vaccine (Sf9 Cells)
  5. A Safety and Immunogenicity Study of Inactivated SARS-CoV-2 Vaccine (Vero Cells) in Healthy Population Aged 18 Years and Above(COVID-19)
  6. A Study to Evaluate Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccine (Vero Cells) in Healthy Population Aged 18 Years and Above(COVID-19)
  7. AZD1222 Vaccine for the Prevention of COVID-19
  8. Clinical Study of Recombinant Novel Coronavirus Vaccine
  9. COVID-19 Vaccine in Immunosuppressed Adults With Autoimmune Diseases (COVIAAD)
  10. Lot-to-lot Consistency of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Healthy Adults
  11. Phase I Trial of a Recombinant SARS-CoV-2 Vaccine (Sf9 Cell)
  12. Phase I Clinical Study of Recombinant Novel Coronavirus Vaccine
  13. Phase I Clinical Trial of Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell)
  14. Phase I Clinical Trial of a COVID-19 Vaccine in 18-60 Healthy Adults (CTCOVID-19)
  15. Phase II Clinical Trial of Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell)
  16. Recombinant New Coronavirus Vaccine (CHO Cells) to Prevent SARS-CoV-2 Phase I Clinical Trial (≥60 Years Old)
  17. Safety and Immunogenicity Study of Inactivated Vaccine for Prevention of SARS-CoV-2 Infection(COVID-19)
  18. Safety and Immunogenicity Study of Inactivated Vaccine for Prophylaxis of SARS CoV-2 Infection (COVID-19)
  19. Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b2) in Chinese Healthy Population Pfizer
  20. Safety of an Inactivated SARS-CoV-2 Vaccine (CoronaVac) in Children and Adolescents
  21. Study on Combined Vaccination With SARS-CoV-2 Inactivated Vaccine and Quadrivalent Influenza Vaccine
  22. Study of the Commercial Scale SARS-CoV-2 Vaccine Against the Pilot Scale Among Adults, and Bridging Study of the Immunogenicity in Elderly Against That in Adults
  23. Study on Heterologous Prime-boost of Recombinant COVID-19 Vaccine (Ad5 Vector) and RBD-based Protein Subunit Vaccine
  24. Study on Sequential Immunization of Inactivated SARS-CoV-2 Vaccine and Recombinant SARS-CoV-2 Vaccine (Ad5 Vector)
  25. The Phase I Clinical Trial of Booster Vaccination of Adenovirus Type-5 Vectored COVID-19 Vaccine
  26. West China Hospital COVID-19 vaccine I
  27. West China Hospital COVID-19 vaccine II
  28. West China Hospital COVID-19 vaccine III

Colombia

  1. A Controlled Phase 2/3 Study of Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Vaccine (SCB-2019) for the Prevention of COVID-19 (SCB-2019)
  2. A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants (ENSEMBLE)
  3. A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults (ENSEMBLE 2) (Janssen)
  4. A Study to Determine the Safety and Efficacy of SARS-CoV-2 mRNA Vaccine CVnCoV in Adults for COVID-19
  5. Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in Adults
  6. Study of Monovalent and Bivalent Recombinant Protein Vaccines Against COVID-19 in Adults 18 Years of Age and Older (VAT00008)

Croatia

  1. COVID-19 Vaccines Safety Tracking (CoVaST)

Cuba

  1. ABDALA Clinical Study Phase III
  2. Evaluation of the safety and immunogenicity of the vaccine candidate CIGB-66 against SARS-CoV-2. (COVID-19)
  3. Phase I study, open, sequential and adaptive for evaluating the safety, reactogenicity and explore the immunogenicity of the prophylactic Vaccine Candidate FINLAY-FR-2 anti SARS-CoV-2 (COVID-19)

Czechia

  1. COVID-19 Vaccines Safety Tracking (CoVaST)
  2. Oral Side Effects of COVID-19 Vaccine

Denmark

  1. National Cohort Study of Effectiveness and Safety of SARS-CoV-2/COVID-19 Vaccines (ENFORCE) (ENFORCE)
  2. Using BCG Vaccine to Protect Health Care Workers in the COVID-19 Pandemic

Dominican Republic

  1. A Controlled Phase 2/3 Study of Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Vaccine (SCB-2019) for the Prevention of COVID-19 (SCB-2019)
  2. A Study to Determine the Safety and Efficacy of SARS-CoV-2 mRNA Vaccine CVnCoV in Adults for COVID-19
  3. Sanofi Phase III

Egypt

  1. A Study to Evaluate The Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) in Healthy Population Aged 18 Years Old and Above (COVID-19)
  2. Immunologic Responses to Single and Double Doses of COVID-19 Vaccines in Egyptians

Estonia

  1. COVID-19 Vaccines Safety Tracking (CoVaST)

Ethiopia

  1. COVID-19 Vaccines Safety Tracking (CoVaST)

Finland

  1. Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Children <12 Years of Age

France

  1. A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults (ENSEMBLE 2) (Janssen)
  2. Allergy and COVID-19 Vaccines (COVALL)
  3. BNT162b2 Vaccination With Two Doses in COVID-19 Negative Adult Volunteers and With a Single Dose in COVID-19 Positive Adult Volunteers (CoviCompareP) (Pfizer)
  4. Clinical Trial to Evaluate the Safety and Immunogenicity of the COVID-19 Vaccine (COVID-19-101)
  5. Cohort Assessing the Immunogenicity and the Safety of the COVID-19 Vaccine Janssen in Healthy Volunteers Based on 2 Age Groups: 65 Years or Older – 55 to 65 Years. Covicompare-Janssen (CoviCompare_J)
  6. Compare Immunological Efficacy of a Vaccine Regimen Combining Two Covid19 mRNA Vaccines (Pfizer-BioNTech and Moderna) With That of a Homologous Vaccination of Each Covid19 mRNA Vaccine (ARNCOMBI)
  7. Monitoring of COVID-19 Vaccine Response in Organ Transplant Patients (COVATRANS)
  8. Phase III Double-blind, Placebo-controlled Study of AZD7442 for Pre-exposure Prophylaxis of COVID-19 in Adult. (PROVENT)
  9. Study Evaluating SARS-CoV-2 (COVID-19) Humoral Response After BNT162b2 Vaccine in Immunocompromised Adults Compared to Healthy Adults (EREVA)

Germany

  1. A Controlled Phase 2/3 Study of Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Vaccine (SCB-2019) for the Prevention of COVID-19 (SCB-2019)
  2. A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults (ENSEMBLE 2) (Janssen)
  3. A Study to Determine the Safety and Efficacy of SARS-CoV-2 mRNA Vaccine CVnCoV in Adults for COVID-19
  4. A Study to Evaluate the Safety and Immunogenicity of Vaccine CVnCoV in Healthy Adults in Germany for COVID-19
  5. A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults
  6. A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults
  7. COVID-19 Vaccines Safety Tracking (CoVaST)
  8. Oral Side Effects of COVID-19 Vaccine
  9. Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in Adults
  10. Saxon SARS-CoV-2 Infection and Vaccination Study in Dialysis Patients, Solid Organ Recipients and Staff (DIA-Vacc)
  11. Study to Assess VPM1002 in Reducing Healthcare Professionals’ Absenteeism in COVID-19 Pandemic
  12. Study to Assess VPM1002 in Reducing Hospital Admissions and/or Severe Respiratory Infectious Diseases in Elderly in COVID-19 Pandemic

Ghana

  1. COVID-19 Vaccines Safety Tracking (CoVaST)
  2. Sanofi Phase III

Greece

  1. Bacillus Calmette-guérin Vaccination to Prevent COVID-19 (ACTIVATEII)
  2. Study of the Kinetics of Antibodies Against COVID-19 (SARS-CoV-2) and of Cellular Subpopulations of the Immune System

Honduras

  1. Study of Monovalent and Bivalent Recombinant Protein Vaccines Against COVID-19 in Adults 18 Years of Age and Older (VAT00008)
  2. Study of Recombinant Protein Vaccines With Adjuvant as a Primary Series and as a Booster Dose Against COVID-19 in Adults 18 Years of Age and Older (VAT00002)

Hong Kong

  1. Antibody Response to COVID-19 Vaccines in Liver Disease Patients

India

  1. A phase III, randomized, multi-centre, double blind, placebo controlled, study to evaluate efficacy, safety and immunogenicity of Novel Corona Virus -2019-nCov vaccine candidate of M/s Cadila Healthcare Limited. 
  2. “A prospective, longitudinal, observational, post licensure vaccine evaluation study to assess the effectiveness of COVID-19 vaccine among the Healthcare workers of Max group of hospitals”.
  3. An Adaptive, Seamless Phase 1, Followed by Phase 2 Randomized, Double-blind, Multicenter Study to Evaluate the Safety, Reactogenicity, Tolerability and Immunogenicity of the Whole-Virion Inactivated SARS-CoV-2 Vaccine (BBV152) in Healthy Volunteers 
  4. An Efficacy and Safety Clinical Trial of an Investigational COVID-19 Vaccine (BBV152) in Adult Volunteers
  5. Biological E initiates human trials of vaccine
  6. Biological E completes phase-2 covid vaccine trial, gets SEC nod for phase-3
  7. Clinical Trial to Assess Safety and Immunogenicity of Gam-COVID-Vac Combined 

Vector Vaccine for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-Сov-2) Infection

  1. Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of ZYIL1 Following Oral Administration in Healthy Volunteers
  2. Coronavirus | Biological E gets nod to start Phase III trials of COVID-19 vaccine
  3. Safety and Immunogenicity of an Intranasal SARS-CoV-2 Vaccine (BBV154) for COVID-19
  4. Oxford-Astrazeneca COVID-19 Vaccine: Phase II trials will begin in India today
  5. Safety and Immunogenicity of a DNA SARS-CoV-2 vaccine (ZyCoV-D): Results of an open-label, non-randomized phase I part of phase I/II clinical study by intradermal route in healthy subjects in India
  6. Sanofi Phase III
  7. Whole-Virion Inactivated SARS-CoV-2 Vaccine (BBV152) for COVID-19 in Healthy Volunteers (BBV152)
  8. Will take another 4-5 months to publish phase 3 trials data of ZyCoV-D vaccine, says Zydus Group MD
  9. Zydus Cadila’s Covid-19 vaccine enters Phase II testing

Indonesia

  1. A Global Phase III Clinical Trial of Recombinant COVID- 19 Vaccine (Sf9 Cells)
  2. Dendritic Cell Vaccine, AV-COVID-19, to Prevent COVID-19 Infection
  3. Efficacy, Safety and Immunogenicity Study of SARS-CoV-2 Inactivated Vaccine (COVID-19)
  4. Preventive Dendritic Cell Vaccine, AV-COVID-19, in Subjects Not Actively Infected With COVID-19

Iran

  1. A double-blinded, randomized, placebo-controlled Phase I Clinical trial to evaluate the safety and immunogenicity of COVID-19 inactivated vaccine (Shif-Pharmed) in a healthy population
  2. A double-blind, randomized, placebo-controlled Phase I Clinical trial to evaluate the safety and immunogenicity of COVID-19 inactivated vaccine (Shifa-Pharmed) in a healthy population aged 51-75 years
  3. A double-blind, randomized, placebo-controlled Phase II/III Clinical trial to evaluate the safety and efficacy of COVID-19 inactivated vaccine (Shifa-Pharmed) in a population aged 18 to 75 years
  4. BNT162b2 Messenger Ribonucleic Acid (mRNA) Covid-19 Vaccine in Cancer Patients on Active Treatment (UNICO)
  5. Efficacy, safety, and immunogenicity of Soberana recombinant vaccine (product of Finlay Institute) based on RBD protein subunit of Sars-Cov-2 in a 2-dose regimen with and without a booster dose: a double-blind, randomized, placebo-controlled phase III clinical trial in the Iranian population of 18-80 years
  6. Phase II Clinical Trial of CinnaGen COVID-19 Vaccine (SpikoGen)

Israel

  1. COVID-19 Vaccine and Ovarian Reserve
  2. Covid-19 Vaccine Effectiveness in Healthcare Personnel in Clalit Health Services in Israel (CoVEHPI) (CoVEHPI)

Italy

  1. COVID19 Vaccination: Clinical, Laboratory and Cellular Monitoring (SAPIENZAVAX)
  2. Effectiveness and Safety of COVID-19 Vaccine in Patients With IBD Treated With Immunomodulatory or Biological Drugs (ESCAPE-IBD) (ESCAPE-IBD)
  3. Effectiveness of mRNA Covid-19 Vaccines on Cancer Patients:Observational Study. (ANTICOV) (ANTICOV)
  4. GRAd-COV2 Vaccine Against COVID-19
  5. Immunogenicity of Covid-19 Vaccination for Patients With Hematological Malignancies
  6. National Project on Vaccines, COVID-19 and Frail Patients (VAX4FRAIL)
  7. Study of GRAd-COV2 for the Prevention of COVID-19 in Adults (COVITAR)

Japan

  1. A Study of TAK-019 in Healthy Japanese Adults (COVID-19)
  2. A Study of TAK-919 in Healthy Japanese Adults (COVID-19)
  3. Drug Use Investigation of COMIRNATY Intramuscular Injection
  4. Phase I Double-blind, Placebo-controlled Study of AZD7442
  5. Phase II / III Study of COVID-19 DNA Vaccine (AG0302-COVID19)
  6. Special Investigation of COMIRNATY in the Population With Underlying Diseases
  7. Study of AZD1222 for the Prevention of COVID-19 in Japan
  8. Study of COVID-19 DNA Vaccine (AG0302-COVID19)
  9. Study of COVID-19 DNA Vaccine (AG0301-COVID19)
  10. Study of DS-5670a (COVID-19 Vaccine) in Japanese Healthy Adults and Elderly Subjects
  11. Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Japanese Adults (Pfizer)
  12. Study of Monovalent and Bivalent Recombinant Protein Vaccines Against COVID-19 in Adults 18 Years of Age and Older (VAT00008)
  13. Survey of the Moderna COVID-19 Vaccine in People at High-Risk of Developing Severe COVID-19 Symptoms

Jordan

  1. A Study to Evaluate The Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) in Healthy Population Aged 18 Years Old and Above (COVID-19)

Kazakhstan

  1. Immunogenicity, Efficacy and Safety of QazCovid-in® COVID-19 Vaccine
  2. Reactogenicity, Safety and Immunogenicity of QazCoVac-P COVID-19 Vaccine
  3. Reactogenicity, Safety and Immunogenicity of QazCovid-in® COVID-19 Vaccine

Kenya

  1. A Global Phase III Clinical Trial of Recombinant COVID- 19 Vaccine (Sf9 Cells)
  2. Sanofi Phase III

Korea

  1. Comirnaty Korea PMS
  2. Safety and Immunogenicity Study of AdCLD-CoV19: A COVID-19 Preventive Vaccine in Healthy Volunteers
  3. Safety and Immunogenicity of GX-19N, a COVID-19 Preventive DNA Vaccine in Elderly Individuals
  4. Safety and Immunogenicity Study of SARS-CoV-2 Nanoparticle Vaccine (GBP510) Adjuvanted With or Without AS03 (COVID-19)
  5. Safety and Immunogenicity Study of SARS-CoV-2 Nanoparticle Vaccine (GBP510) Adjuvanted With Aluminum Hydroxide (COVID-19)
  6. Safety and Immunogenicity of a SARS-CoV-2 Vaccine (NBP2001) in Healthy Adults (COVID-19)
  7. Safety, Tolerability and Immunogenicity of INO-4800 Followed by Electroporation in Healthy Volunteers for COVID19

Mexico

  1. A Phase 1b Trial to Evaluate Safety and Effect of SAR443122 on Immune System in Severe COVID-19
  2. A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants (ENSEMBLE)
  3. A Study to Determine the Safety and Efficacy of SARS-CoV-2 mRNA Vaccine CVnCoV in Adults for COVID-19
  4. A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years) at Risk for SARS-CoV-2
  5. COVID-19 Vaccines Safety Tracking (CoVaST)
  6. Prevention, Efficacy and Safety of BCG Vaccine in COVID-19 Among Healthcare Workers
  7. Sanofi Phase III
  8. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Neutralizing Antibody BGB-DXP593 in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)
  9. Study of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine in Adults

Mongolia

  1. Tableted COVID-19 Therapeutic Vaccine (COVID-19)

Morocco

  1. A Phase III clinical trial for inactivated novel coronavirus pneumonia (COVID-19) vaccine (Vero cells)

Nepal

  1. A Controlled Phase 2/3 Study of Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Vaccine (SCB-2019) for the Prevention of COVID-19 (SCB-2019)

Netherlands

  1. A Study of Ad26.COV2.S in Healthy Adults (COVID-19)
  2. A Study to Determine the Safety and Efficacy of SARS-CoV-2 mRNA Vaccine CVnCoV in Adults for COVID-19    
  3. A Trial Among HealthCare Workers (HCW) Vaccinated With Janssen Vaccine: the SWITCH Trial (SWITCH)
  4. Anti-COVID19 AKS-452 – ACT Study (ACT)
  5. BCG Vaccination to Protect Healthcare Workers Against COVID-19 (BRACE)
  6. Reducing COVID-19 Related Hospital Admission in Elderly by BCG Vaccination
  7. Reducing Health Care Workers Absenteeism in Covid-19 Pandemic Through BCG Vaccine (BCG-CORONA)
  8. Vaccination Against COVID-19 in Cancer (VOICE)

Nigeria

  1. Sanofi Phase III

Norway

  1. Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) Immune Kidney Transplant Study (COVID-19) (SCV-KTx-imm)

Pakistan

  1. Sanofi Phase III

Panama

  1. A Controlled Phase 2/3 Study of Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Vaccine (SCB-2019) for the Prevention of COVID-19 (SCB-2019)
  2. A Dose-Confirmation Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19
  3. A Study to Determine the Safety and Efficacy of SARS-CoV-2 mRNA Vaccine CVnCoV in Adults for COVID-19

Peru

  1. A Dose-Confirmation Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19
  2. A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants (ENSEMBLE)
  3. A Study to Determine the Safety and Efficacy of SARS-CoV-2 mRNA Vaccine CVnCoV in Adults for COVID-19
  4. Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru (Covid-Peru)
  5. Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in Adults

Philippines

  1. A Controlled Phase 2/3 Study of Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Vaccine (SCB-2019) for the Prevention of COVID-19 (SCB-2019)
  2. A Global Phase III Clinical Trial of Recombinant COVID- 19 Vaccine (Sf9 Cells)
  3. A Multi-center, Randomized, Double-blind, Placebo-controlled Phase II/III Clinical Trial to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 Inactivated (Vero Cell) Vaccine in the Elderly 60-80 Years of Age, Coronovac ENCOV19 Study
  4. A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults (ENSEMBLE 2) (Janssen)

Poland

  1. A Controlled Phase 2/3 Study of Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Vaccine (SCB-2019) for the Prevention of COVID-19 (SCB-2019)
  2. COVID-19 Vaccines Safety Tracking (CoVaST)
  3. Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Children <12 Years of Age

Portugal

  1. COVID-19 Vaccines Safety Tracking (CoVaST)

Puerto Rico

  1. A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years) at Risk for SARS-CoV-2
  2. SARS-CoV-2 Immune Responses After COVID-19 Therapy and Subsequent Vaccine

Russia

  1. An Open Study of the Safety, Tolerability and Immunogenicity of “Gam-COVID-Vac Lyo” Vaccine Against COVID-19
  2. An Open Study on the Safety, Tolerability, and Immunogenicity of “Sputnik Light” Vaccine
  3. An Open Study of the Safety, Tolerability and Immunogenicity of the Drug “Gam-COVID-Vac” Vaccine Against COVID-19
  4. AZD1222 Vaccine for the Prevention of COVID-19
  5. Clinical Trial of Efficacy, Safety, and Immunogenicity of Gam-COVID-Vac Vaccine Against COVID-19 (RESIST)
  6. Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) Against COVID-19
  7. COVID-19 Vaccines Safety Tracking (CoVaST)
  8. Study of the EpiVacCorona Vaccine With the Involvement of Volunteers Aged 60 Years and Above
  9. Study of the Safety, Reactogenicity and Immunogenicity of “EpiVacCorona” Vaccine for the Prevention of COVID-19 (EpiVacCorona)
  10. Study of the Tolerability, Safety, Immunogenicity and Preventive Efficacy of the EpiVacCorona Vaccine for the Prevention of COVID-19
  11. Study to Evaluate Efficacy, Immunogenicity and Safety of the Sputnik-Light (SPUTNIK-LIGHT)
  12. The Study of “Gam-COVID-Vac” Vaccine Against COVID-19 With the Participation of Volunteers of 60 y.o and Older

Serbia

  1. COVID-19 Vaccines Safety Tracking (CoVaST)

Senegal

  1. Efficacy and Safety Evaluation of Treatment Regimens in Adult COVID-19 Patients in Senegal (SEN-CoV-Fadj)

Singapore

  1. Ascending Dose Study of Investigational SARS-CoV-2 Vaccine ARCT-021 in Healthy Adult Subjects
  2. A Trial Evaluating the Safety and Effects of an RNA Vaccine ARCT-021 in Healthy Adults

Slovakia

  1. Oral Side Effects of COVID-19 Vaccine

Slovenia

  1. COVID-19 Vaccines Safety Tracking (CoVaST)

South Africa

  1. A Controlled Phase 2/3 Study of Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Vaccine (SCB-2019) for the Prevention of COVID-19 (SCB-2019)
  2. A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants (ENSEMBLE)
  3. A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults (ENSEMBLE 2)
  4. A Study of Ad26.COV2.S in Healthy Pregnant Participants (COVID-19) (HORIZON 1)
  5. COVID-19 Vaccine (ChAdOx1 nCoV-19) Trial in South African Adults With and Without HIV-infection
  6. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Neutralizing Antibody BGB-DXP593 in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)
  7. A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults (ENSEMBLE 2) (Janssen)
  8. Study to Evaluate the Safety and Efficacy of a Booster Dose of BNT162b2 Against COVID-19 in Participants ≥16 Years of Age.

Spain

  1. A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults (ENSEMBLE 2) (Janssen)
  2. A Study to Determine the Safety and Efficacy of SARS-CoV-2 mRNA Vaccine CVnCoV in Adults for COVID-19
  3. BCG Vaccination to Protect Healthcare Workers Against COVID-19 (BRACE)
  4. Phase III Double-blind, Placebo-controlled Study of AZD7442 for Pre-exposure Prophylaxis of COVID-19 in Adult. (PROVENT)
  5. Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Children <12 Years of Age
  6. Vaccination With COMIRNATY in Subjects With a VAXZEVRIA First Dose (CombiVacS)

Sweden

  1. COVID-19 Vaccination of Immunodeficient Persons (COVAXID) (COVAXID)

Switzerland

  1. Immunocompromised Swiss Cohorts Based Trial Platform (COVERALL)

Taiwan

  1. A Study to Evaluate MVC-COV1901 Vaccine Against COVID-19 in Adult (COVID-19)
  2. A Study to Evaluate MVC-COV1901 Vaccine Against COVID-19 in Elderly Adults
  3. A Study to Evaluate the Safety and Immunogenicity of COVID-19 (AdimrSC-2f) Vaccine
  4. A Study o Evaluate the Safety, Tolerability, and Immunogenicity of MVC-COV1901, CT-COV-21 Sub-study
  5. A Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-612 COVID-19 Vaccine
  6. A Study to Evaluate UB-612 COVID-19 Vaccine in Adolescent, Younger and Elderly Adult Volunteers

Turkey

  1. Clinical Trial For SARS-CoV-2 Vaccine (COVID-19)
  2. Comparative Evaluation of Covid-19 Vaccines Response
  3. Efficacy, Immunogenicity and Safety of Inactivated ERUCOV-VAC Compared With Placebo in COVID-19
  4. Efficacy, Immunogenicity, and Safety of the Inactivated COVID-19 Vaccine (TURKOVAC) Versus the CoronaVac Vaccine
  5. Evaluation of the Effect and Side Effect Profile of Covid-19 Vaccine in Cancer Patients
  6. Safety and Immunogenicity of Two Different Strengths of the Inactivated COVID-19 Vaccine ERUCOV-VAC (ERUCOV-VAC)
  7. Study of a Severe Acute Respiratory Syndrome CoV-2 (SARS-CoV-2) Virus-like Particle (VLP) Vaccine in Healthy Adults (COVID-19)

Uganda

  1. Safety and Immunogenicity of LNP-nCOV saRNA-02 Vaccine Against SARS-CoV-2, the Causative Agent of COVID-19 (COVAC-Uganda)

United Arab Emirates

  1. A Phase III clinical trial for inactivated novel coronavirus pneumonia (COVID-19) vaccine (Vero cells)
  2. A Study to Evaluate The Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) in Healthy Population Aged 18 Years Old and Above (COVID-19)
  3. Immuno-bridging Study of Inactivated SARS-CoV-2 Vaccine in Healthy Population Aged 3-17 vs Aged 18 Years Old and Above (COVID-19)

United Kingdom

  1. A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults (ENSEMBLE 2) (Janssen)
  2. A Study of a Candidate COVID-19 Vaccine (COV001)
  3. A Study Looking at the Effectiveness, Immune Response, and Safety of a COVID-19 Vaccine in Adults in the United Kingdom
  4. BCG Vaccination to Protect Healthcare Workers Against COVID-19 (BRACE)
  5. CROWN CORONATION: COVID-19 Research Outcomes Worldwide Network for CORONAvirus prevenTION (CROWN CORONA)
  6. Dose Finding Study to Evaluate Safety, Tolerability and Immunogenicity of an Inactiviated Adjuvanted Sars-Cov-2 Virus Vaccine Candidate Against Covid-19 in Healthy Adults
  7. Investigating a Vaccine Against COVID-19
  8. Phase III Double-blind, Placebo-controlled Study of AZD7442 for Pre-exposure Prophylaxis of COVID-19 in Adult. (PROVENT)
  9. Safety and Immunogenicity of COVI-VAC, a Live Attenuated Vaccine Against COVID-19
  10. Study of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine in Adults
  11. Study To Compare The Immunogenicity Against COVID-19, Of VLA2001 Vaccine To AZD1222 Vaccine (COV-COMPARE)

United States

  1. A Clinical Observational Study of SARS-CoV-2 Specific CD8 T-Cell Responses to COVID-19 Vaccines in Humans
  2. A Open-label Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab
  3. A Phase 3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of Multiple Production Lots and Dose Levels of BNT162b2 RNA-Based COVID-19 Vaccines Against COVID-19 in Healthy Participants
  4. A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants (ENSEMBLE)
  5. A Study of Ad26.COV2.S in Adults (COVID-19)
  6. A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults (ENSEMBLE 2) (Janssen)
  7. A Study of Ad26.COV2.S in Healthy Pregnant Participants (COVID-19) (HORIZON 1)
  8. A Study of SARS CoV-2 Infection and Potential Transmission in Individuals Immunized With Moderna COVID-19 Vaccine (CoVPN 3006)
  9. A Study to Assess Safety, Tolerability, and Immunogenicity of V591 (COVID-19 Vaccine) in Healthy Participants (V591-001)
  10. A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years) at Risk for SARS-CoV-2
  11. A Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 Vaccine in Adolescents 12 to <18 Years Old to Prevent COVID-19 (TeenCove)
  12. A Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 Vaccines in Healthy Adults Between 18 Years and 55 Years of Age to Prevent COVID-19
  13. A Study to Evaluate the Immunogenicity and Safety of mRNA-1273.211 Vaccine for COVID-19 Variants
  14. A Study to Evaluate Safety and Immunogenicity of mRNA-1273 Vaccine to Prevent COVID-19 in Adult Organ Transplant Recipients and in Healthy Adult Participants
  15. A Study to Evaluate Safety and Effectiveness of mRNA-1273 COVID-19 Vaccine in Healthy Children Between 6 Months of Age and Less Than 12 Years of Age
  16. A Synthetic MVA-based SARS-CoV-2 Vaccine, COH04S1, for the Prevention of COVID-19
  17. A Trial Evaluating the Safety and Effects of an RNA Vaccine ARCT-021 in Healthy Adults
  18. A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants With Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants With Solid Tumors on PD1/PDL1 Inhibitor Therapy
  19. Chimpanzee Adenovirus and Self-Amplifying mRNA Prime-Boost Prophylactic Vaccines Against SARS-CoV-2 in Healthy Adults National Institute of Allergy and Infectious Diseases (NIAID)
  20. CORVax12: SARS-CoV-2 Spike (S) Protein Plasmid DNA Vaccine Trial for COVID-19 (SARS-CoV-2) (CORVax12)
  21. COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders
  22. COVID-19 Oral and Subcutaneous Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenovirus Platform in Healthy Volunteers in USA
  23. COVID-19 Protection After Transplant Pilot Study (CPAT)
  24. COVID19 SARS Vaccinations: Systemic Allergic Reactions to SARS-CoV-2 Vaccinations (SARS)
  25. COVID-19 Study to Assess Immunogenicity, Safety, and Tolerability of Moderna mRNA-1273 Vaccine Administered With Casirivimab+Imdevimab in Healthy Adult Volunteers
  26. COVID-19 Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenoviral-COVID-19 in Normal Healthy Volunteers
  27. COVID-19 Vaccines Safety Tracking (CoVaST)
  28. COVID-19 VAX Booster Dosing in Patients With Hematologic Malignancies
  29. Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) After Receipt of EUA Vaccines National Institute of Allergy and Infectious Diseases (NIAID)
  30. Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 COVID-19 Vaccine in Adults Aged 18 Years and Older
  31. Dose Ranging Trial to Assess Safety and Immunogenicity of V590 (COVID-19 Vaccine) in Healthy Adults (V590-001)
  32. Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS Nanoparticle Vaccine With/Without Matrix-M Adjuvant
  33. Evaluation of the Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Participants With Acute Respiratory Distress Syndrome (ARDS) Associated With at Least Severe COVID-19
  34. Immune Response to the COVID-19 Vaccine
  35. Immune Responses in Oncology Patients to Novel Coronavirus Vaccines (IROC)
  36. Immunity After COVID-19 Vaccination
  37. Moderna COVID-19 Vaccine mRNA-1273 Observational Pregnancy Outcome Study
  38. mRNA Based-Covid-19 Vaccine Effects on Blood Glucose Levels
  39. Pfizer-BioNTech COVID-19 BNT162b2 Vaccine Effectiveness Study – Kaiser Permanente Southern California
  40. Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in Adults
  41. Phase III Double-blind, Placebo-controlled Study of AZD7442 for Pre-exposure Prophylaxis of COVID-19 in Adult. (PROVENT)
  42. Polio Vaccine (IPV) for SARS-CoV-2 and Prevention of Coronavirus Disease (COVID-19)
  43. Post COVID-19 Vaccination Analysis in Healthcare Worker Recipients
  44. Safety and Immunogenicity Study of 20vPnC When Coadministered With a Booster Dose of BNT162b2
  45. Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV-2 Infection (COVID-19)
  46. Safety and Immunogenicity Study of a SARS-CoV-2 (COVID-19) Variant Vaccine (mRNA-1273.351) in Naïve and Previously Vaccinated Adults
  47. Safety and Immunogenicity Trial of an Oral SARS-CoV-2 Vaccine (VXA-CoV2-1) for Prevention of COVID-19 in Healthy Adults
  48. Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers
  49. Safety, Tolerability, and Pharmacokinetics of SAB-185 in Healthy Participants
  50. Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Healthy Seronegative Adults at High Risk of SARS-CoV-2 Exposure
  51. Safety and Immunogenicity Study of 20vPnC When Coadministered With a Booster Dose of BNT162b2
  52. SARS-CoV-2 Immune Responses After COVID-19 Therapy and Subsequent Vaccine
  53. SARS-CoV-2 Vaccine (COH04S1) Versus Emergency Use Authorization SARS-COV-2 Vaccine for the Treatment of COVID-19 in Patients With Blood Cancer
  54. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Neutralizing Antibody BGB-DXP593 in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)
  55. Study of a Quadrivalent High-Dose Influenza Vaccine and a Moderna COVID-19 Vaccine Administered Either Concomitantly or Singly in Participants 65 Years of Age and Older Previously Vaccinated With a 2-dose Schedule of Moderna COVID-19 Vaccine
  56. Study of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine in Adults
  57. Study of Recombinant Protein Vaccine Formulations Against COVID-19 in Healthy Adults 18 Years of Age and Older
  58. Study of Recombinant Protein Vaccines With Adjuvant as a Primary Series and as a Booster Dose Against COVID-19 in Adults 18 Years of Age and Older (VAT00002)
  59. Study to Evaluate the Safety, Tolerability, and Immunogenicity of Multiple Formulations of BNT162b2 Against COVID-19 in Healthy Adults
  60. Study to Evaluate the Safety and Efficacy of a Booster Dose of BNT162b2 Against COVID-19 in Participants ≥16 Years of Age.
  61. Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Children <12 Years of Age
  62. Study of Monovalent and Bivalent Recombinant Protein Vaccines Against COVID-19 in Adults 18 Years of Age and Older (VAT00008)
  63. The Impact of Vaccination on Severity of Illness in COVID-19
  64. The Safety of Administering a Second Dose of a COVID-19 mRNA Vaccine in Individuals Who Experienced a Systemic Allergic Reaction to an Initial Dose
  65. Vaccination for Recovered Inpatients With COVID-19 (VATICO)
  66. Vaccine-generated Immunity in Ocrelizumab-treated Patients: Longitudinal Assessments (VIOLA)

Vietnam

  1. A Study to Evaluate MVC-COV1901 Vaccine Against COVID-19 in Adult (COVID-19)
  2. Study to Evaluate the Safety, Immunogenicity, and Efficacy of Nanocovax Vaccine Against COVID-19

Unknown

  1. Study to Evaluate Safety, Tolerability & Immunogenicity of BNT162b2 in Immunocompromised Participants ≥2 Years